Last edition
News about "UNLOXCYT NCCN recommendation"
Sun Pharma's Unloxcyt Gets Preferred NCCN Status
Sun Pharma's UNLOXCYT has received a Category 2A preferred designation in the updated NCCN guidelines for locally advanced Cutaneous Squamous Cell Carcinoma (laCSCC).
UNLOXCYT NCCN Recommendation | 21/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members